- Home
- AVX vs BEAT Comparison
AVX vs BEAT Comparison
Compare AVX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVX | BEAT |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Canada | United States |
| Employees | 7 | 16 |
| Industry | Metal Fabrications | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 53.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AVX | BEAT |
|---|---|---|
| Price | $0.54 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 350.9K | ★ 611.2K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $0.54 |
| 52 Week High | $2.27 | $4.00 |
Technical Indicators
Market Signals| Indicator | AVX | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 43.06 |
| Support Level | $0.46 | $0.81 |
| Resistance Level | $0.61 | $1.26 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 39.34 | 9.53 |
Price Performance
Historical ComparisonAbout AVX Avax One Technology Ltd.
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. It focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.